ToplinePresident Donald Trump said Cracker Barrel should “go back to the old logo” after the restaurant chain sparked consumer backlash for adopting a text-only logo, ditching the man leaning on a barrel, leading critics to accuse the company of abandoning its classic American Southern feel.Cracker Barrel is replacing a logo that included a man and a barrel with a text-only version. (Photo by Tim Boyle/Getty Images)Getty ImagesKey FactsTrump said in a Tuesday morning Truth Social post the restaurant chain s ...

Glenstar Minerals Inc. Announces Closing of Upsized $3 Million Private Placement FinancingAugust 26, 2025 12:25 PM EDT | Source: Glenstar Minerals Inc.Vancouver, British Columbia--(Newsfile Corp. - August 26, 2025) - Glenstar Minerals Inc. (CSE: GSTR) ("Glenstar" or the "Company") is pleased to announce that it has closed its previously announced commercially reasonable efforts private placement of 4,500,000 units (the "Units") of the Company at a price of $0.68 per Unit (the "Offering") throu ...

Subscribers to Chart of the Week received this commentary on Sunday, August 24.This week’s Big Tech rout drove the broader market to substantial losses throughout the week. Leading the push lower were (seemingly impenetrable) large cap tech titans Palantir Technologies (PLTR) and Nvidia (NVDA). The pair suffered an (overdue) bout of profit taking, which resulted in respective losses of 9.4% and 3.5% on Aug. 19.The Nasdaq-100 Index (NDX) shuttered 1.4% on the same day; testing, breaching, and ultimately recl ...

Core Viewpoint - Catalyst Pharmaceuticals (CPRX) has entered into a settlement agreement with Lupin Pharmaceuticals regarding patent litigation over Firdapse, which protects the company's sales from generic competition until February 25, 2035 [1][5][6]. Group 1: Firdapse Overview - Firdapse is approved in the U.S., EU, and Japan for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults and has recently expanded its label to include pediatric patients aged six and older [2]. - In 2024, Firdapse accounted for 62% of Catalyst Pharmaceuticals' sales, generating $168.6 million in revenue in the first half of 2025 [5][8]. Group 2: Settlement Details - The settlement prohibits Lupin from marketing its generic version of Firdapse in the U.S. before February 25, 2035, unless specific exceptions arise [6]. - The agreement also resolves all ongoing patent litigation between Catalyst Pharmaceuticals/SERB and Lupin in the U.S. District Court in New Jersey [6][7]. Group 3: Other Products and Market Position - Catalyst Pharmaceuticals markets two additional drugs in the U.S.: Fycompa for epilepsy and Agamree for Duchenne muscular dystrophy, which provide incremental revenue [9]. - The patents for Fycompa are set to expire in 2025 and 2026, leading to anticipated declines in sales due to increased competition from generics [10].

Economic Indicators - Durable Goods Orders for July decreased by -2.8%, an improvement from the consensus estimate of -4.0% and the previous month's -9.4%, which was the lowest since April 2020 [2] - Excluding Transportation orders, Durable Goods Orders increased by +1.1%, the highest since September of the previous year [3] - Shipments of Durable Goods showed a +0.7% increase, marking the strongest performance of 2025 so far [3] Housing Market - Case-Shiller Home Prices for June rose by +2.1%, which is 20 basis points below expectations and down from +2.8% in May, representing the lowest level since July 2023 [4] - Year-over-year Housing Wealth increased by +1.9%, which is below the inflation rate of +2.7% in June [4] - New York City saw a +7.0% increase in housing value over the past year, while Tampa, San Francisco, and Dallas experienced declines of -2.4%, -2.0%, and -1.0% respectively [5] Company News - Eli Lilly reported a -10.5% average reduction in body weight from its phase-3 testing of a new weight loss pill, with shares up +2.5% following the announcement [6] - The Bank of Montreal (BMO) exceeded earnings expectations by +9.9%, reporting $2.33 per share compared to the consensus of $2.12, while The Bank of Nova Scotia (BNS) reported a +7% earnings beat at $1.37 per share versus the expected $1.28 [7]

Core Insights - Immuneering Corporation (IMRX) has entered into a clinical supply agreement with Eli Lilly (LLY) for the KRAS G12C inhibitor, olomorasib (LY3537982) [1] - The agreement supports a planned phase II study evaluating Immuneering's atebimetinib (IMM-1-104) in combination with olomorasib for treating advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) [2] - Immuneering's shares rose by 21.7% following the announcement, and the stock has increased by 170.5% year-to-date compared to the industry's 4.1% rise [2][3] Agreement Details - The combination of atebimetinib and olomorasib is expected to provide a vertical blockade of the RAS-MAPK pathway, with preclinical data showing enhanced tumor regression and prolonged survival compared to monotherapy [5] - This is Immuneering's second collaboration announcement in 2025, following a similar agreement with Regeneron Pharmaceuticals to evaluate atebimetinib with Libtayo for advanced NSCLC [6][7] - In both agreements, Immuneering retains full worldwide development and commercialization rights to atebimetinib [8] Ongoing Studies - Immuneering is advancing atebimetinib in other cancer studies, including a phase IIa study in combination with modified gemcitabine/nab-paclitaxel for first-line pancreatic cancer [9] - Preliminary data from this study indicated a 94% overall survival and 72% progression-free survival at six months, with updated data expected later in Q3 2025 [10] - The company plans to initiate a pivotal study for atebimetinib in combination with modified gemcitabine/nab-paclitaxel in 2026, pending regulatory feedback [11]

Group 1 - The United States now owns a 10% stake in Intel, which is seen as a strategic move to reduce dependence on foreign chip manufacturers, particularly TSMC in Taiwan, which is vulnerable to China [1][2] - Analyst Ben Thompson argues that while there are issues with US ownership in Intel, it is better than the alternative of Intel not existing, emphasizing the importance of chips for AI and other technologies [1][2] - There is speculation that similar equity stakes may be pursued by the Trump administration in other critical industries, such as defense contractors like Lockheed Martin, as part of a broader strategy [2][3] Group 2 - The Intel deal has been likened to a real estate transaction, where the US government may require companies to pay for amendments to existing agreements [7][8] - Intel CEO Lip-Bu Tan's request for Trump to stop calling for his resignation highlights the potential for other CEOs to negotiate different terms with the administration [9] - The Trump administration's recent actions, including a 15% export tax on Nvidia and AMD, indicate a trend towards taking direct stakes in companies rather than just imposing fees [10][11]

Core Points - The total number of shares composing the company's capital as of July 31, 2025, is 38,038,784 [2] - The gross total of voting rights is also 38,038,784, which includes shares that have voting rights as well as those deprived of voting rights [2] - The net total of voting rights is 38,005,304, calculated by subtracting treasury shares from the gross total [2] Legal Compliance - The declaration is established in accordance with Article L.233-8 II of the French Code de Commerce and Article 223-11 of the Règlement Général of the Autorité des marchés financiers (AMF) [1] - There are no special statutory obligations beyond the legal notification requirements for crossing thresholds established by French law [2]

Core Insights - The article discusses Alphabet Inc. (commonly known as Google) and highlights its successful leverage of AI technology, which supports a positive outlook on the stock [1]. Company Analysis - Alphabet Inc. has been recognized for effectively utilizing artificial intelligence to enhance its business operations and market position [1]. - The analyst previously issued a buy rating on Alphabet's stock, indicating confidence in its growth potential [1]. Investment Philosophy - The investment philosophy emphasized in the article focuses on simplicity, suggesting that fundamental financial ratios and metrics provide clearer insights than complex analyses [1]. - The analyst maintains a close watch on market trends, particularly within the technology sector, which is crucial for identifying investment opportunities [1].

Core Viewpoint - Oklo's stock is experiencing significant growth, driven by positive analyst sentiment regarding its potential in the nuclear energy sector, particularly in relation to small modular reactors (SMRs) [1][3]. Group 1: Analyst Opinions - Bank of America analyst Dimple Gosai has initiated coverage on Oklo with a buy rating and a price target of $92, suggesting a potential upside of 29.2% from the previous closing price of $71.19 [3]. - Gosai believes Oklo is well positioned to meet the increasing energy demands associated with artificial intelligence, and its pipeline includes memoranda of understanding totaling approximately 14 gigawatts, setting it apart from other SMR competitors [4]. Group 2: Market Sentiment and Risks - Despite Bank of America's bullish outlook, not all analysts share the same perspective; UBS has initiated coverage with a neutral rating and a price target of $65, indicating a more cautious approach [5]. - Oklo currently lacks a design licensed by the Nuclear Regulatory Commission, which adds a higher degree of risk to the investment, making it more suitable for speculative investors [6].